Lonza and Crucell Enter Cell Culture Agreement
PERMEXCIS medium was developed for the cultivation of PER.C6 cells and has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines.
25/09/08 Lonza and Crucell N.V. have entered into a co-exclusive global manufacturing, sales and distribution agreement related to the PERMEXCIS cell culture medium developed by Crucell for PER.C6 cells. Under this agreement Lonza will manufacture, market and sell the medium on a global basis. Financial details of the agreement were not disclosed.
The PERMEXCIS medium is a chemically defined cell culture medium that does not contain human- or animal-derived components. PERMEXCIS medium was developed for the cultivation of PER.C6 cells and has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines. This novel medium has proven, in a comparison study performed by Crucell, to provide higher viral vaccine product yields in PER.C6-based manufacturing processes than some of the currently marketed media for PER.C6 cells.
“Lonza is pleased to enter into this agreement with Crucell N.V. Lonza is a leader in cell culture technology and media manufacturing , with a broad range of specialized media for all the major cell lines used in the biopharmaceutical industry. The new PER.C6 medium is a complementary addition to the Lonza Serum Free Medium product range,” said Roel Gordijn, Global Sales and Marketing Director for Media in the Bioscience business of Lonza.
